EVMN ▼ -8.6% - Evommune, Inc. $EVMN Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress Evommune shares fell 8.6% today following the company's announcement of a late-breaker Phase 2a presentation for its atopic dermatitis candidate EVO301 at the EADV 2026 Congress. The timing and characterization of the data presentation suggest investor concerns about the trial results, though specific efficacy or safety details were not disclosed in the announcement. 23-SEP-2026 04:05 PM ET